+91-8668442535

Trigeminal Neuralgia Treatment Market By Treatment (Drug Based, Surgery) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

This report on the global trigeminal neuralgia treatment market investigates various drugs used for trigeminal neuralgia treatment, as well as a pipeline analysis of upcoming potential drugs. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain.

According to the International Association for the Study of Pain, the incidence of trigeminal neuralgia is 12 per 100,000 people per year. The etiology includes the compression of blood vessels, degeneration of arteries, myelin sheath infiltration, and idiopathy.

Trigeminal neuralgia is most commonly seen after the age of 40 and is more common in women. Thus, the drug pipeline for the trigeminal neuralgia treatment market comprises potential drugs that are more target-specific and possess innovative properties.

For the purpose of this study, the various treatment types studied include drug-based therapy and surgical procedures; further, drug-based therapy is segmented as anticonvulsant drugs, NSAIDs, and opioids.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The pipeline analysis for the trigeminal neuralgia treatment market includes estimated market sales of Phase III drugs through 2025. We have estimated sales of very specific molecules based on the type (chemical-based or biological), sponsor, depicted peak sales by leading market experts, and other factors.

The global trigeminal neuralgia treatment market is segmented geographically into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from the face to the brain. The etiology includes the compression of blood vessels, degeneration of arteries, myelin sheath infiltration, and idiopathy. According to the American Association of Neurological Surgeons, 150,000 people are diagnosed with trigeminal neuralgia. Trigeminal neuralgia is most commonly seen after the age of 40.

Based on the treatment type, the trigeminal neuralgia treatment market is segmented into:

Drug-based

  • Anticonvulsant
  • NSAIDs
  • Opioids

Surgery

  • Rhizotomy
  • Stereotactic radiosurgery
  • Microvascular decompression

According to market experts, drug-based therapy is increasingly being used to treat in developed markets, but its use in emerging markets remains low. Carbamazepine is the only approved drug on the market and is considered first-line therapy, followed by NSAIDs and opioids.

However, the drug-related side effects are high, so patients are opting for various types of surgical procedures for the treatment of trigeminal neuralgia, like microvascular decompression, rhizotomy, and stereotactic radiosurgery. In the base year of 2016, drug-based therapy accounted for the major market share in the treatment industry at around 71%, followed by surgical procedures, which accounted for the remaining 29% of patients who were not responding to drug therapy.

During the forecast period of 2017–2025, drug-based therapy is expected to experience significant growth. The key factors assisting the segment's growth comprise patient-supportive reimbursement policies that have assisted the increased use of drug-based therapy in developed markets, a rise in the aging population coupled with growing public awareness, and technological advancements in surgical procedures.

For the purpose of this study, the global trigeminal neuralgia treatment market is categorized into:

  •  North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

North America was observed as the largest market for trigeminal neuralgia treatment in the base year of 2016 due to a rise in the aging population and technological advancements in diagnostic tests. Europe is expected to be the second-largest market due to rising public awareness, healthcare infrastructure, and the penetration of new technologies.

According to the American Association of Neurological Surgeons, 150,000 people are diagnosed with trigeminal neuralgia. Growth in Asia-Pacific in the trigeminal neuralgia treatment market is attributed to factors like the rising prevalence of neuropathic pain diseases, increasing investments in R&D, and higher disposable income in these regions.

However, factors such as developing health infrastructure, increasing awareness among people about health care, and an aging population are going to fuel the rapid growth of the trigeminal neuralgia disease treatment market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Question:

The market for Trigeminal Neuralgia Treatment Market is expected to reach USD$ 99.17 Mn in 2025.

The Trigeminal Neuralgia Treatment Market is expected to see significant CAGR growth over the coming years, at 7.60%.

he report is forecasted from 2017 -2025.

The base year of this report is 2016.

Allergan Plc,Biogen, Inc.,Kineta Inc.,Merz Pharma GmbH & Co.,Trigemina Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Apr 2017
Category:  Pharmaceuticals
Report ID:   58387
Report Format:   PDF
Pages:   120
Rating:    4.6 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support